OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
High-altitude treatment in atopic and nonatopic patients with severe asthma Source: Eur Respir J 2012; 40: 1374-1380 Year: 2012
The reduction of the house dust mite as a prevention component in a treatment of the asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 335s Year: 2002
Levels of house dust mites (HDM) in homes of patients with bronchial asthma (BA) and the airway inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 281s Year: 2001
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
House dust mite allergen exposure is associated with sensitisation and asthma in New Zealand infants Source: Eur Respir J 2002; 20: Suppl. 38, 117s Year: 2002
Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
The effect of anti-mite mattress covers on mite allergen levels in the PIAMA (prevention and incidence of asthma and mite allergy) study Source: Eur Respir J 2001; 18: Suppl. 33, 321s Year: 2001
Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Association between house dust mites (HDM) level in homes of atopic children and interleukine-4 and IgE in expired air condensate(EAC) Source: Eur Respir J 2002; 20: Suppl. 38, 536s Year: 2002
Exposure to higher levels of house dust mite allergen and endotoxin is not associated with respiratory symptoms and severity of AHR in older asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 454s Year: 2002
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
LSC 2014 abstract - Influenza-induced exacerbation in a murine chronic house dust mite (HDM) asthma model Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014
Late Breaking Abstract - Budget impact of introducing 12SQ HDM SLIT-tablet for house dust mite allergic asthma in Spain Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Respiratory symptoms in relation to indoor exposure to mite and cat allergens and endotoxins Source: Eur Respir J 2001; 18: 555-563 Year: 2001
The bell tolls for the relationship between house dust mite exposure and asthma in childhood Source: Eur Respir Rev 2008; 17: 96-98 Year: 2008